|MDACC Study No:||2012-0866 (clinicaltrials.gov NCT No: NCT01757535)|
|Title:||A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO COMPARE EFFICACY AND SAFETY OF ORAL AZACITIDINE PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE AS MAINTENANCE THERAPY IN SUBJECTS WITH ACUTE MYLOID LEUKEMIA IN COMPLETE REMISSION |
|Principal Investigator:||Farhad Ravandi-Kashani|
|Study Description:||The goal of this clinical research study is to learn taking oral azacitidine |
can help keep the disease from returning. In this study, azacitidine will be
compared with a placebo. The safety and tolerability of oral azacitidine will
also be studied.
Azacitidine is designed to block certain proteins in cancer cells whose job is
to stop the function of the tumor-fighting proteins. By blocking the "bad"
proteins, the tumor-fighting genes may be able to work better.
A placebo is not a drug. It looks like the study drug but is not designed to
treat any disease or illness. It is designed to be compared with a study drug
to learn if the study drug has any real effect.